Back to the archive

The encyclopedia · Finance & Accounting · Financial decision · 2020–2024

Elanco called channel-stuffing 'strong demand' and paid the SEC $15M

Quarter-end rebates and extended payment terms filled distributors' warehouses — Elanco told investors the growth was consumer demand.

Elanco Animal Health

What happened

Elanco Animal Health, spun off from Eli Lilly in 2018, told investors its revenue growth reflected strong consumer demand for its pet-health and farm-animal products. The SEC found that a significant part of that growth came from quarter-end incentivized sales to distributors — rebates and extended payment terms that pulled forward revenue and built excess inventory in the channel.

Elanco did not disclose that its growth depended on these incentives, or the reasonably likely risk that the channel inventory would depress future revenue. Its periodic reports and earnings releases were inaccurate or incomplete as a result.

In November 2024 Elanco agreed to pay a $15 million civil penalty and accept a cease-and-desist order.

Why it happened

  • Quarter-end incentives are the fastest way to hit a revenue target, and the cost — future revenue pulled forward — does not show up until the next quarter.
  • Telling investors the growth was demand-driven made the numbers look sustainable when they were not.
  • Channel inventory is invisible to the income statement until the distributor stops ordering.
What it cost$15M SEC penaltyembarrassing

The lesson

Revenue bought with quarter-end incentives is a loan from next quarter — and the investors you tell it is demand are the ones who will notice when the loan comes due.

Sources

spotted an error? The club wants to know.

Comments · 0

    Sign in to join the comments.

    More like this

    Somewhere, someone solved the problem this company failed at. 2nd Opinion →